November 2023 Medical News Summary

Nov 30, 2023

Why Physicians Don’t Deprescribe Medicines; What to Know About Wegovy’s Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug

Related Content:

• As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging
• FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management
• Deciding When It’s Better to Deprescribe Medicines Than to Continue Them